AKBA PE Ratio & Valuation,Is AKBA Overvalued

AKBA Relative Valuation

AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKBA is overvalued; if below, it's undervalued.

Historical Valuation

Akebia Therapeutics Inc (AKBA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.71 is considered Undervalued compared with the five-year average of -3.43. The fair price of Akebia Therapeutics Inc (AKBA) is between 7.53 to 9.11 according to relative valuation methord. Compared to the current price of 1.66 USD , Akebia Therapeutics Inc is Undervalued By 77.95%.

Relative Value

Fair Zone

7.53-9.11

Current Price：1.66

77.95%

Undervalued

85.13

0.00

EV/EBITDA

Akebia Therapeutics Inc. (AKBA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.01. The thresholds are as follows: Strongly Undervalued below -3.85, Undervalued between -3.85 and -2.43, Fairly Valued between 0.40 and -2.43, Overvalued between 0.40 and 1.82, and Strongly Overvalued above 1.82. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

17.26

EV/EBIT

Akebia Therapeutics Inc. (AKBA) has a current EV/EBIT of 17.26. The 5-year average EV/EBIT is 5.50. The thresholds are as follows: Strongly Undervalued below -168.51, Undervalued between -168.51 and -81.51, Fairly Valued between 92.51 and -81.51, Overvalued between 92.51 and 179.52, and Strongly Overvalued above 179.52. The current Forward EV/EBIT of 17.26 falls within the Historic Trend Line -Fairly Valued range.

1.71

Akebia Therapeutics Inc. (AKBA) has a current PS of 1.71. The 5-year average PS is 1.75. The thresholds are as follows: Strongly Undervalued below -0.29, Undervalued between -0.29 and 0.73, Fairly Valued between 2.77 and 0.73, Overvalued between 2.77 and 3.79, and Strongly Overvalued above 3.79. The current Forward PS of 1.71 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Akebia Therapeutics Inc. (AKBA) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.28. The thresholds are as follows: Strongly Undervalued below -49.58, Undervalued between -49.58 and -27.93, Fairly Valued between 15.37 and -27.93, Overvalued between 15.37 and 37.02, and Strongly Overvalued above 37.02. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

20.96

P/FCF

Akebia Therapeutics Inc. (AKBA) has a current P/FCF of 20.96. The 5-year average P/FCF is 4.88. The thresholds are as follows: Strongly Undervalued below -63.19, Undervalued between -63.19 and -29.15, Fairly Valued between 38.92 and -29.15, Overvalued between 38.92 and 72.96, and Strongly Overvalued above 72.96. The current Forward P/FCF of 20.96 falls within the Historic Trend Line -Fairly Valued range.

Akebia Therapeutics Inc (AKBA) has a current Price-to-Book (P/B) ratio of 10.59. Compared to its 3-year average P/B ratio of 1.42 , the current P/B ratio is approximately 643.96% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about 417.88% higher. Akebia Therapeutics Inc (AKBA) has a Forward Free Cash Flow (FCF) yield of approximately 7.30%. Compared to its 3-year average FCF yield of -18.32%, the current FCF yield is approximately -139.86% lower. Relative to its 5-year average FCF yield of -53.62% , the current FCF yield is about -113.62% lower.

10.59

P/B

Median3y

1.42

Median5y

2.04

7.30

FCF Yield

Median3y

-18.32

Median5y

-53.62

Competitors Valuation Multiple

The average P/S ratio for AKBA's competitors is 31.17, providing a benchmark for relative valuation. Akebia Therapeutics Inc Corp (AKBA) exhibits a P/S ratio of 1.71, which is -94.52% above the industry average. Given its robust revenue growth of 57.01%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AKBA decreased by 12.63% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 37.43M to 58.77M.

The secondary factor is the P/E Change, contributed 32.08%to the performance.

Overall, the performance of AKBA in the past 1 year is driven by Revenue Growth. Which is more sustainable.

57.01%

37.43M → 58.77M

Revenue Growth

-101.72%

-53.54 → 0.92

Margin Expansion

32.08%

-19.40 → -25.62

P/E Change

-12.63%

1.90 → 1.66

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Akebia Therapeutics Inc (AKBA) currently overvalued or undervalued?

What is Akebia Therapeutics Inc (AKBA) fair value?

AKBA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Akebia Therapeutics Inc (AKBA) is between 7.53 to 9.11 according to relative valuation methord.

How does AKBA's valuation metrics compare to the industry average?

What is the current P/B ratio for Akebia Therapeutics Inc (AKBA) as of Dec 15 2025?

As of Dec 15 2025, Akebia Therapeutics Inc (AKBA) has a P/B ratio of 10.59. This indicates that the market values AKBA at 10.59 times its book value.

What is the current FCF Yield for Akebia Therapeutics Inc (AKBA) as of Dec 15 2025?

As of Dec 15 2025, Akebia Therapeutics Inc (AKBA) has a FCF Yield of 7.30%. This means that for every dollar of Akebia Therapeutics Inc’s market capitalization, the company generates 7.30 cents in free cash flow.

What is the current Forward P/E ratio for Akebia Therapeutics Inc (AKBA) as of Dec 15 2025?

As of Dec 15 2025, Akebia Therapeutics Inc (AKBA) has a Forward P/E ratio of 85.13. This means the market is willing to pay $85.13 for every dollar of Akebia Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Akebia Therapeutics Inc (AKBA) as of Dec 15 2025?

As of Dec 15 2025, Akebia Therapeutics Inc (AKBA) has a Forward P/S ratio of 1.71. This means the market is valuing AKBA at $1.71 for every dollar of expected revenue over the next 12 months.

AKBA Valuation